Effects of oral administration of a commercial activated charcoal suspension on serum osmolality and lactate concentration in the dog

Journal of Veterinary Internal Medicine

Volumn 19, Issue 5, 2005, Pages 683-686

  Burkitt, Jamie M ^a   Haskins, Steve C ^a   Aldrich, Janet ^a   Jandrey, Karl E ^a   Rezende, Marlis L ^a   Boyle, Jennifer E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Decontamination; Hyperlactatemia; Hyperosmolality; Osmolal gap; Toxicity

Indexed keywords

CHARCOAL; DRUG VEHICLE; GLYCEROL; LACTIC ACID DERIVATIVE; PROPYLENE GLYCOL;

ANIMAL; ANIMAL DISEASE; AREA UNDER THE CURVE; ARTICLE; BLOOD; BLOOD GAS ANALYSIS; CHEMICALLY INDUCED DISORDER; DOG; DOSE RESPONSE; DRINKING; DRUG EFFECT; ORAL DRUG ADMINISTRATION; OSMOLARITY; SLEEP STAGE; UREA NITROGEN BLOOD LEVEL; VEHICLES; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BLOOD GAS ANALYSIS; BLOOD UREA NITROGEN; CHARCOAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; GLYCEROL; LACTATES; OSMOLAR CONCENTRATION; PROPYLENE GLYCOL; SLEEP STAGES; VEHICLES; VOMITING;

CANIS FAMILIARIS;

EID: 26844473890     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2005)19[683:EOOAOA]2.0.CO;2     Document Type: Article

References (42)

1. Cate JC, Hedrick R. Propylene glycol intoxication and lactic acidosis. N Engl J Med 1980;303:1237.
2. Lehman A, Newman H. Propylene glycol: Rate of metabolism, absorption, and excretion, with a method for estimation in body fluids. J Pharmacol Exp Ther 1937;60:312-322.
3. Morshed KM, Nagpaul JP, Majumdar S, et al. Kinetics of oral propylene glycol-induced acute hyperlactatemia. Biochem Med Metab Biol 1989;42:87-94.
4. Saini M, Amma MK, Dash S, et al. Hematological alterations in propylene glycol-dosed female rats are minimal. Vet Hum Toxicol 1996;38:81-85.
5. Morshed KM, Nagpaul JP, Majumdar S, et al. Kinetics of propylene glycol elimination and metabolism in rat. Biochem Med Metab Biol 1988;39:90-97.
6. Yu DK, Elmquist WF, Sawchuk RJ. Pharmacokinetics of propylene glycol in humans during multiple dosing regimens. J Pharm Sci 1985;74:876-879.
7. Van Winkle W. Quantitative gastrointestinal absorption and renal excretion of propylene glycol. J Pharmacol Exp Ther 1941;72:344-353.
8. van der Westhuyzen JH, Berger GM, Beyers N, et al. Iatrogenic hyperosmolality in a neonate. A case report. S Afr Med J 1981;60:996-998.
9. Tourtellotte WW, Reinglass JL, Newkirk TA. Cerebral dehydration action of glycerol. I. Historical aspects with emphasis on the toxicity and intravenous administration. Clin Pharmacol Ther 1972;13:159-171.
10. Rottenberg DA, Hurwitz BJ, Posner JB. The effect of oral glycerol on intraventricular pressure in man. Neurology 1977;27:600-608.
11. Johnson V, Carlson AJ, Johnson A. Studies on the physiological action of glycerol on the animal organism. Am J Physiol 1933;103:517-534.
12. Wittman JS III, Bawin RR. Stimulation of gluconeogenesis by propylene glycol in the fasting rat. Life Sci 1974;15:515-524.
13. Miller ON, Bazzano G. Propanediol metabolism and its relation to lactic acid metabolism. Ann N Y Acad Sci 1965;119:957-973.
14. Rudney H. Propanediol phosphate as a possible intermediate in the metabolism of acetone. J Biol Chem 1954;210:361-371.
15. Newman HW, Van Winkle W, Kennedy NK, et al. Comparative effects of propylene glycol, other glycols, and alcohol on the liver directly. J Pharmacol Exp Ther 1940;68:194-200.
16. Frank MS, Nahata MC, Hilty MD. Glycerol: A review of its pharmacology, pharmacokinetics, adverse reactions, and clinical use. Pharmacotherapy 1981;1:147-160.
17. Robergs RA, Griffin SE. Glycerol. Biochemistry, pharmacokinetics and clinical and practical applications. Sports Med 1998;26:145-167.
18. Swanson RE, Thompson RB. Renal tubular handling of glycerol and ethylene glycol in the dog. Am J Physiol 1969;217:553-562.
19. Fulop M, Brenner BM. Diuretic action of glycerol in dogs. Proc Soc Exp Biol Med 1967;124:893-897.
20. Parker MG, Fraser GL, Watson DM, et al. Removal of propylene glycol and correction of increased osmolar gap by hemodialysis in a patient on high dose lorazepam infusion therapy. Intensive Care Med 2002;28:81-84.
21. Demey HE, Daelemans RA, Verpooten GA, et al. Propylene glycol-induced side effects during intravenous nitroglycerin therapy. Intensive Care Med 1988;14:221-226.
22. Fligner CL, Jack R, Twiggs GA, et al. Hyperosmolality induced by propylene glycol. A complication of silver sulfadiazine therapy. JAMA 1985;253:1606-1609.
23. Cawley MJ. Short-term lorazepam infusion and concern for propylene glycol toxicity: Case report and review. Pharmacotherapy 2001;21:1140-1144.
24. Reynolds HN, Teiken P, Regan ME, et al. Hyperlactatemia, increased osmolar gap, and renal dysfunction during continuous lorazepam infusion. Crit Care Med 2000;28:1631-1634.
25. Keiner MJ, Bailey DN. Propylene glycol as a cause of lactic acidosis. J Anal Toxicol 1985;9:40-42.
26. Demey H, Daelemans R, De Broe ME, et al. Propylene glycol intoxication due to intravenous nitroglycerin. Lancet 1984;1:1360.
27. Murch S, Costeloe K. Hyperosmolality related to propylene glycol in an infant. BMJ 1990;301:389.
28. Huggon I, James I, Macrae D. Hyperosmolality related to propylene glycol in an infant treated with enoximone infusion. BMJ 1990;301:19-20.
29. Glasgow AM, Boeckx RL, Miller MK, et al. Hyperosmolality in small infants due to propylene glycol. Pediatrics 1983;72:353-355.
30. Kulick MI, Lewis NS, Bansal V, et al. Hyperosmolality in the burn patient: Analysis of an osmolal discrepancy. J Trauma 1980;20:223-228.
31. MacDonald MG, Fletcher AB, Johnson EL, et al. The potential toxicity to neonates of multivitamin preparations used in parenteral nutrition. J Parenter Enteral Nutr 1987;11:169-171.
32. Bekeris L, Baker C, Fenton J, et al. Propylene glycol as a cause of an elevated serum osmolality. Am J Clin Pathol 1979;72:633-636.
33. Kulick MI, Wong R, Okarma TB, et al. Prospective study of side effects associated with the use of silver sulfadiazine in severely burned patients. Ann Plast Surg 1985;14:407-419.
34. Hershey SD, Gursel E. Hyperosmolality caused by percutaneously absorbed glycerin in a burned patient. J Trauma 1982;22:250-252.
35. Cantore G, Guidetti B, Virno M. Oral glycerol for the reduction of intracranial pressure. J Neurosurg 1964;21:278-283.
36. Connally HE. Critical care monitoring considerations for the diabetic patient. Clin Tech Small Anim Pract 2002;17:73-78.
37. Firth A. Treatments used in small animal toxicoses. In: Murphy MJ, Bonagura JD, eds. Kirk's Current Veterinary Therapy. Philadelphia, PA: WB Saunders; 2000:207-211.
38. Rosendale ME. Decontamination strategies. Vet Clin North Am Small Anim Pract 2002;32:311-321.
39. Plumb DC, ed. Charcoal, activated. In: Plumb DC, ed. Veterinary Drug Handbook, 4th ed. White Bear Lake, MN: PharmaVet Publishing; 2002:162-163.
40. Fort FL, Heyman IA, Kesterson JW. Hemolysis study of aqueous polyethylene glycol 400, propylene glycol and ethanol combinations in vivo and in vitro. J Parenter Sci Technol 1984;38:82-87.
41. Seidenfeld MA, Hanzlik PJ. The general properties, actions and toxicity of propylene glycol. J Pharmacol Exp Ther 1932;44:109-121.
42. Christopher MM, Perman V, Eaton JW. Contribution of propylene glycol-induced Heinz body formation to anemia in cats. J Am Vet Med Assoc 1989;194:1045-1056.